Selexipag - NS 304 | ACT 293987 | Uptravi

Based on 38 publications in PubMed 9 10 38

Axon 2605

CAS [475086-01-2]

MF C26H32N4O4S
MW 496.62

  • Purity: 100%
  • Soluble in DMSO

Selexipag

Description

Orally available and long-acting prodrug of MRE 269, a potent and highly selective IP receptor agonist (Ki values 20 nM and 260 nM for inhibition of [3H]iloprost binding to human IP receptor by MRE 269 and Selexipag, respectively). Capable of ameliorating vascular endothelial dysfunction, pulmonary arterial wall hypertrophy, and right ventricular hypertrophy. Furthermore, Selexipag (NS 304) elevated right ventricular systolic pressure and improved survival in a rat model of pulmonary hypertension induced by monocrotaline (MCT).

KEYWORDS: Selexipag | supplier | IP agonist prodrug | NS 304 | ACT 293987 | NS304 | ACT293987 | CAS [475086-01-2] - [1267423-51-7] | Prostaglandins | PGI2 (IP) | Agonist | MRE269 | prodrug | prostacyclin | PGI2 | pulmonary | hypertension | vascular | endothelial | dysfunction | hypertrophy

Order
Size Unit Price Stock
5 mg €90.00 In Stock
25 mg €335.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...